| scholarly article | Q13442814 |
| P50 | author | Marc C Johnson | Q60374298 |
| Paul Bieniasz | Q54632854 | ||
| P2093 | author name string | Trinity Zang | |
| David Perez-Caballero | |||
| Matthew W McNatt | |||
| Devon A Gregory | |||
| Alaleh Ebrahimi | |||
| P2860 | cites work | Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2 | Q21559418 |
| Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin | Q24318564 | ||
| Antiviral actions of interferons | Q24550676 | ||
| Inhibition of Lassa and Marburg virus production by tetherin | Q24652263 | ||
| Plasma membrane is the site of productive HIV-1 particle assembly | Q27334953 | ||
| HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress | Q28207991 | ||
| Expression cloning of PIG-L, a candidate N-acetylglucosaminyl-phosphatidylinositol deacetylase | Q28570907 | ||
| Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology | Q28580409 | ||
| Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu | Q29547836 | ||
| The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein | Q29619540 | ||
| Retrovirus budding | Q29619900 | ||
| HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane | Q30815492 | ||
| Quantitative membrane proteomics reveals new cellular targets of viral immune modulators | Q33269787 | ||
| Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants | Q33408799 | ||
| Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells | Q33862227 | ||
| Nef proteins from simian immunodeficiency viruses are tetherin antagonists. | Q34658653 | ||
| Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion | Q37115275 | ||
| Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. | Q37115285 | ||
| Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. | Q37120188 | ||
| Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network | Q37157197 | ||
| HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor | Q39872885 | ||
| An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein | Q40051211 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| virion | Q1757347 | ||
| identical protein binding | Q14762994 | ||
| Bone marrow stromal cell antigen 2 | Q21100505 | ||
| P304 | page(s) | 499-511 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Tetherin inhibits HIV-1 release by directly tethering virions to cells | |
| P478 | volume | 139 |
| Q57252413 | A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism |
| Q33292303 | A Genetic Screen Identifies a Critical Role for the WDR81-WDR91 Complex in the Trafficking and Degradation of Tetherin. |
| Q34220959 | A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. |
| Q39350800 | A facile quantitative assay for viral particle genesis reveals cooperativity in virion assembly and saturation of an antiviral protein. |
| Q67405976 | A lipid-based partitioning mechanism for selective incorporation of proteins into membranes of HIV particles. |
| Q36387986 | A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins |
| Q34668033 | A new approach to establish a cell line with reduced risk of endogenous retroviruses. |
| Q34929498 | A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release |
| Q34211506 | A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo |
| Q36376142 | A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2. |
| Q30382586 | A tail of Tetherin: how pandemic HIV-1 conquered the world. |
| Q28384647 | Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells |
| Q38692134 | Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathway. |
| Q27010123 | An evolutionary perspective on the broad antiviral specificity of MxA |
| Q39005453 | Analysis of determinants in filovirus glycoproteins required for tetherin antagonism |
| Q39707294 | Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. |
| Q30423656 | Animal models for HIV/AIDS research |
| Q39898727 | Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. |
| Q33553369 | Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment |
| Q39383826 | Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts |
| Q35531194 | Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells |
| Q35686784 | Antiretroviral restriction factors |
| Q34623866 | Antiretroviral restriction factors in mice |
| Q33807551 | Antiviral activity of the interferon-induced cellular protein BST-2/tetherin |
| Q24635271 | Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction |
| Q34123690 | Antiviral potency and functional analysis of tetherin orthologues encoded by horse and donkey |
| Q38489344 | Apolipoprotein E-dependent differences in innate immune responses of maturing human neuroepithelial progenitor cells exposed to HIV-1. |
| Q34742397 | Assembly and replication of HIV-1 in T cells with low levels of phosphatidylinositol-(4,5)-bisphosphate. |
| Q41816646 | BST-2 Diminishes HIV-1 Infectivity |
| Q34905536 | BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action |
| Q39667774 | BST-2 mediated restriction of simian-human immunodeficiency virus |
| Q33631179 | BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer. |
| Q24630382 | BST-2/tetherin: a new component of the innate immune response to enveloped viruses |
| Q39278440 | BST-2/tetherin: viral tether, viral sensor or both? |
| Q39034818 | BST2/CD317 counteracts human coronavirus 229E productive infection by tethering virions at the cell surface |
| Q21559401 | BST2/Tetherin enhances entry of human cytomegalovirus |
| Q35544442 | BST2/tetherin inhibition of alphavirus exit |
| Q21559656 | BST2/tetherin inhibits dengue virus release from human hepatoma cells |
| Q90015819 | Beyond Tethering the Viral Particles: Immunomodulatory Functions of Tetherin (BST-2) |
| Q26774878 | Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses |
| Q28510187 | Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo |
| Q36208162 | Bst2/Tetherin Is Induced in Neurons by Type I Interferon and Viral Infection but Is Dispensable for Protection against Neurotropic Viral Challenge |
| Q39611736 | Budding capability of the influenza virus neuraminidase can be modulated by tetherin |
| Q35562726 | C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif |
| Q92487810 | CD317 Activates EGFR by Regulating Its Association with Lipid Rafts |
| Q27468925 | CD317 Promotes the survival of cancer cells through apoptosis-inducing factor |
| Q34325965 | CD317/tetherin is an organiser of membrane microdomains |
| Q33826740 | CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection |
| Q37428581 | CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules |
| Q34291056 | Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells |
| Q39222387 | Cell-cell transmission allows human T-lymphotropic virus 1 to circumvent tetherin restriction |
| Q34544718 | Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. |
| Q33743176 | Characterization of E3 ligases involved in lysosomal sorting of the HIV-1 restriction factor BST2. |
| Q33867470 | Cloning and characterization of the antiviral activity of feline Tetherin/BST-2 |
| Q37589650 | Cocaine Enhances DC to T-cell HIV-1 Transmission by Activating DC-SIGN/LARG/LSP1 Complex and Facilitating Infectious Synapse Formation |
| Q36245641 | Coevolutionary dynamics between tribe Cercopithecini tetherins and their lentiviruses. |
| Q104480742 | Comparative Transcriptome Analysis Reveals the Intensive Early Stage Responses of Host Cells to SARS-CoV-2 Infection |
| Q95601314 | Comparative transcriptome analysis reveals the intensive early-stage responses of host cells to SARS-CoV-2 infection |
| Q41877699 | Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. |
| Q34505213 | Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV |
| Q28730542 | Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene |
| Q28659945 | Counteraction of the multifunctional restriction factor tetherin |
| Q92019600 | Current advances in HIV vaccine preclinical studies using Macaque models |
| Q38748567 | Deletion of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein, vFLIP, from the viral genome compromises the activation of STAT1-responsive cellular genes and spindle cell formation in endothelial cells |
| Q41065951 | Determinants in HIV-2 Env and tetherin required for functional interaction |
| Q34416492 | Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein |
| Q24629504 | Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin |
| Q30360141 | Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. |
| Q27316022 | Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles |
| Q64949513 | Distinct Requirements for HIV-1 Accessory Proteins during Cell Coculture and Cell-Free Infection. |
| Q37701191 | Diverse viral glycoproteins as well as CD4 co-package into the same human immunodeficiency virus (HIV-1) particles. |
| Q28607463 | Early Vertebrate Evolution of the Host Restriction Factor Tetherin |
| Q30419742 | Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir |
| Q36043214 | Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin |
| Q40359568 | Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal |
| Q39614822 | Ebolavirus Replication and Tetherin/BST-2. |
| Q30397332 | Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain |
| Q35067382 | Efficient infection, activation, and impairment of pDCs in the BM and peripheral lymphoid organs during early HIV-1 infection in humanized rag2⁻/⁻γ C⁻/⁻ mice in vivo |
| Q39668496 | Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. |
| Q35982916 | Env-less endogenous retroviruses are genomic superspreaders |
| Q34408687 | Epitope tags beside the N-terminal cytoplasmic tail of human BST-2 alter its intracellular trafficking and HIV-1 restriction |
| Q38158955 | Equine infectious anemia and equine infectious anemia virus in 2013: a review |
| Q37547504 | Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. |
| Q34684340 | Evidence that Vpu modulates HIV-1 Gag-envelope interaction towards envelope incorporation and infectivity in a cell type dependent manner |
| Q26852372 | Evolution of foamy viruses: the most ancient of all retroviruses |
| Q52579749 | Evolution-guided structural and functional analyses of the HERC family reveals an ancient marine origin and determinants of antiviral activity. |
| Q28533773 | Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation |
| Q47424549 | FRET Analysis of the Promiscuous yet Specific Interactions of the HIV-1 Vpu Transmembrane Domain |
| Q38326209 | Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. |
| Q35076983 | Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection |
| Q36086707 | Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein |
| Q36594734 | Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression |
| Q92005460 | Friend retrovirus studies reveal complex interactions between intrinsic, innate and adaptive immunity |
| Q57043865 | From APOBEC to ZAP: Diverse mechanisms used by cellular restriction factors to inhibit virus infections |
| Q37336745 | Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions |
| Q34231846 | Functional mechanisms of the cellular prion protein (PrP(C)) associated anti-HIV-1 properties |
| Q33871635 | Functional microarray analysis suggests repressed cell-cell signaling and cell survival-related modules inhibit progression of head and neck squamous cell carcinoma |
| Q34511101 | HERV-K(HML-2), a seemingly silent subtenant - but still waters run deep |
| Q35902681 | HIV Restriction Factors and Mechanisms of Evasion |
| Q37375080 | HIV accessory proteins versus host restriction factors |
| Q37945213 | HIV-1 Virological Synapse: Live Imaging of Transmission |
| Q37384691 | HIV-1 Vpu - an ion channel in search of a job. |
| Q40677862 | HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites |
| Q39175785 | HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A. |
| Q39696123 | HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment |
| Q33887674 | HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. |
| Q38281996 | HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface |
| Q39536992 | HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction |
| Q24296630 | HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions |
| Q24619066 | HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms |
| Q39417033 | HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin |
| Q97886770 | HM1.24/BST-2 is constitutively poly-ubiquitinated at the N-terminal amino acid in the cytoplasmic domain |
| Q64078553 | Herpes Simplex Virus Evasion of Early Host Antiviral Responses |
| Q42266919 | Herpes simplex virus 1 counteracts tetherin restriction via its virion host shutoff activity |
| Q47230024 | High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release |
| Q37252004 | Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches |
| Q61807398 | Host and Viral Proteins Modulating Ebola and Marburg Virus Egress |
| Q37890247 | Host factors involved in retroviral budding and release. |
| Q36548179 | Host restriction factors in retroviral infection: promises in virus-host interaction |
| Q34298213 | How Ebola virus counters the interferon system |
| Q90440626 | How HIV Nef Proteins Hijack Membrane Traffic To Promote Infection |
| Q40285743 | Hrs inhibits citron kinase-mediated HIV-1 budding via its FYVE domain |
| Q54260280 | Human Intestinal Epithelial Cells Release Antiviral Factors That Inhibit HIV Infection of Macrophages. |
| Q30425799 | Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein |
| Q31086787 | Identification and functional analysis of three isoforms of bovine BST-2 |
| Q35792954 | Identification of BST-2/tetherin-induced hepatitis B virus restriction and hepatocyte-specific BST-2 inactivation |
| Q35028829 | Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach |
| Q34426491 | Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities |
| Q39114721 | Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu |
| Q41922332 | Identifying Restriction Factors for Hemorrhagic Fever Viruses: Dengue and Junín |
| Q28472771 | Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane |
| Q34434913 | Immunogenetics of small ruminant lentiviral infections |
| Q35382088 | In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity |
| Q35170879 | In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans |
| Q36270509 | Increased BST2 expression during simian immunodeficiency virus infection is not a determinant of disease progression in rhesus monkeys |
| Q34405097 | Influenza A virus does not encode a tetherin antagonist with Vpu-like activity and induces IFN-dependent tetherin expression in infected cells |
| Q37385830 | Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin |
| Q36052469 | Influenza virus partially counteracts restriction imposed by tetherin/BST-2. |
| Q47550785 | Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane |
| Q38170229 | Innate antiviral immune signaling, viral evasion and modulation by HIV-1. |
| Q51574130 | Innate barriers to viral infection. |
| Q33997880 | Innate immune recognition and activation during HIV infection |
| Q38160779 | Innate immune responses to HIV infection in the central nervous system |
| Q38491184 | Innate immunity against HIV-1 infection |
| Q35696991 | Innate immunity in acute HIV-1 infection |
| Q39243642 | Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. |
| Q34561070 | Insights into cellular factors that regulate HIV-1 replication in human cells |
| Q54478839 | Interferon-induced SCYL2 limits release of HIV-1 by triggering PP2A-mediated dephosphorylation of the viral protein Vpu. |
| Q24302747 | Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms |
| Q28585561 | Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons |
| Q34114819 | Interferon-inducible effector mechanisms in cell-autonomous immunity |
| Q35742006 | Interferon-stimulated genes and their antiviral effector functions |
| Q34405609 | Interferon-stimulated genes: a complex web of host defenses |
| Q92703239 | Interplay between Intrinsic and Innate Immunity during HIV Infection |
| Q33826655 | Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses |
| Q37899341 | Intracellular defenses against HIV, viral evasion and novel therapeutic approaches |
| Q28659575 | Intrinsic cellular defenses against human immunodeficiency viruses |
| Q30954229 | Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. |
| Q39538757 | Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. |
| Q38697270 | Japanese encephalitis virus counteracts BST2 restriction via its envelope protein E. |
| Q57027519 | Latent human cytomegalovirus enhances HIV-1 infection in CD34 progenitor cells |
| Q36807121 | Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines |
| Q59354447 | Limiting Respiratory Viral Infection by Targeting Antiviral and Immunological Functions of BST-2/Tetherin: Knowledge and Gaps |
| Q34885158 | Long Non-Coding RNA BST2/BISPR is Induced by IFN and Regulates the Expression of the Antiviral Factor Tetherin. |
| Q42369135 | Long Non-coding RNAs in Hepatitis C Virus-Infected Cells. |
| Q40927400 | MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. |
| Q38282025 | Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane |
| Q41927990 | Making Sense of Multifunctional Proteins: Human Immunodeficiency Virus Type 1 Accessory and Regulatory Proteins and Connections to Transcription |
| Q28534707 | Mechanism of HIV-1 virion entrapment by tetherin |
| Q38688274 | Mechanisms of HIV-1 Control |
| Q33828507 | Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers |
| Q38211428 | Mechanisms underlying HIV-1 Vpu-mediated viral egress |
| Q35536281 | Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly |
| Q39649986 | Membrane raft association of the Vpu protein of human immunodeficiency virus type 1 correlates with enhanced virus release |
| Q30397761 | Modulation of HIV-1-host interaction: role of the Vpu accessory protein |
| Q92989829 | Modulation of Innate Immune Signaling Pathways by Herpesviruses |
| Q37658537 | Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo |
| Q42979548 | Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin |
| Q34536269 | Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses |
| Q36355811 | Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapy |
| Q33650914 | Molecular evolution of the primate antiviral restriction factor tetherin |
| Q34645914 | Molecular mechanism of arenavirus assembly and budding |
| Q47555946 | Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature |
| Q36735631 | Mutation of Glycosylation Sites in BST-2 Leads to Its Accumulation at Intracellular CD63-Positive Vesicles without Affecting Its Antiviral Activity against Multivesicular Body-Targeted HIV-1 and Hepatitis B Virus |
| Q47141408 | Myeloid Cell Interaction with HIV: A Complex Relationship. |
| Q92239576 | Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1 |
| Q36307738 | New insights into HIV assembly and trafficking |
| Q58698873 | Nomenclature for endogenous retrovirus (ERV) loci |
| Q34389186 | Oligomerization state and supramolecular structure of the HIV‐1 Vpu protein transmembrane segment in phospholipid bilayers |
| Q40610377 | Origins and Evolution of tetherin, an Orphan Antiviral Gene. |
| Q43433320 | Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin |
| Q93081405 | Plasma Membrane-Associated Restriction Factors and Their Counteraction by HIV-1 Accessory Proteins |
| Q33933111 | Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity |
| Q59354068 | Polymorphisms in Rhesus Macaque Tetherin Are Associated with Differences in Acute Viremia in Simian Immunodeficiency Virus Δ-Infected Animals |
| Q30369981 | Positioning of cysteine residues within the N-terminal portion of the BST-2/tetherin ectodomain is important for functional dimerization of BST-2. |
| Q37820816 | Properties and functions of the nucleocapsid protein in virus assembly |
| Q37013972 | Protective Role of BST2 Polymorphisms in Mother-to-Child Transmission of HIV-1 and Adult AIDS Progression. |
| Q28478446 | Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction |
| Q39084005 | RNA helicase MOV10 functions as a co-factor of HIV-1 Rev to facilitate Rev/RRE-dependent nuclear export of viral mRNAs |
| Q89777325 | RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells |
| Q24296650 | Rab7A is required for efficient production of infectious HIV-1 |
| Q35030956 | Regulation of Interferon-Stimulated Gene BST2 by a lncRNA Transcribed from a Shared Bidirectional Promoter |
| Q34666503 | Relationships between plasma membrane microdomains and HIV-1 assembly |
| Q26767362 | Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and Persistence |
| Q38823675 | Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism. |
| Q92646111 | Resilience of BST-2/Tetherin structure to single amino acid substitutions |
| Q60046078 | Restriction Factors: From Intrinsic Viral Restriction to Shaping Cellular Immunity Against HIV-1 |
| Q42234287 | Restriction of Retroviral Replication by Tetherin/BST-2. |
| Q37895742 | Retroviral restriction and dependency factors in primates and carnivores |
| Q41743410 | Retroviral retention activates a Syk-dependent HemITAM in human tetherin. |
| Q84985844 | Rhesus monkey TRIM5α has distinct HIV-1 restriction activity among different mammalian cell lines |
| Q35383008 | Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens |
| Q36760105 | Roles played by capsid-dependent induction of membrane curvature and Gag-ESCRT interactions in tetherin recruitment to HIV-1 assembly sites |
| Q33916620 | SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release |
| Q36409352 | Sensitivity to BST-2 restriction correlates with Orthobunyavirus host range |
| Q35383228 | Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin |
| Q35531294 | Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu. |
| Q35758867 | Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors |
| Q34146128 | Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu |
| Q36281167 | Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference |
| Q84315458 | Severe acute respiratory syndrome coronavirus spike protein counteracts BST2‐mediated restriction of virus‐like particle release |
| Q35036587 | Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages |
| Q37378819 | Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism. |
| Q36141193 | Smart self-assembled hybrid hydrogel biomaterials |
| Q35383070 | Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo |
| Q37335524 | Soybean-derived Bowman-Birk Inhibitor (BBI) Inhibits HIV Replication in Macrophages |
| Q39230459 | Stimulation of NF-κB activity by the HIV restriction factor BST2. |
| Q35607295 | Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism |
| Q27665937 | Structural and Biophysical Analysis of BST-2/Tetherin Ectodomains Reveals an Evolutionary Conserved Design to Inhibit Virus Release |
| Q27664759 | Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations |
| Q24306855 | Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain |
| Q47155329 | Structural determinant of BST-2-mediated regulation of breast cancer cell motility: a role for cytoplasmic tail tyrosine residues |
| Q27664987 | Structural insight into the mechanisms of enveloped virus tethering by tetherin |
| Q33740120 | Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. |
| Q41849777 | T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication |
| Q34144143 | TIM-family proteins inhibit HIV-1 release. |
| Q36578830 | TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse. |
| Q35076765 | TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements |
| Q39654362 | Tethered virions are intermediates in the assembly and release of HIV-1 particles |
| Q30393226 | Tetherin Antagonism by HIV-1 Group M Nef Proteins |
| Q30853698 | Tetherin Inhibits Cell-Free Virus Dissemination and Retards Murine Leukemia Virus Pathogenesis |
| Q30376050 | Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase. |
| Q37827428 | Tetherin and its viral antagonists |
| Q33674461 | Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. |
| Q31172123 | Tetherin can restrict cell-free and cell-cell transmission of HIV from primary macrophages to T cells |
| Q42746331 | Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. |
| Q37607851 | Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes |
| Q59350998 | Tetherin inhibits Nipah virus but not Ebola virus replication in fruit bat cells |
| Q35038590 | Tetherin inhibits prototypic foamy virus release |
| Q35518677 | Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo |
| Q34180302 | Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. |
| Q38933327 | Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins |
| Q30497822 | Tetherin restricts direct cell-to-cell infection of HIV-1. |
| Q37336851 | Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M |
| Q27314339 | Tetherin restricts productive HIV-1 cell-to-cell transmission |
| Q34819697 | Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis |
| Q41990109 | Tetherin/BST-2 is essential for the formation of the intracellular virus-containing compartment in HIV-infected macrophages. |
| Q36548512 | Tetherin/BST-2 promotes dendritic cell activation and function during acute retrovirus infection. |
| Q30385433 | Tetherin/BST-2: Restriction Factor or Immunomodulator? |
| Q33815533 | The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation |
| Q35300078 | The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin |
| Q35808638 | The Emerging Roles of Viroporins in ER Stress Response and Autophagy Induction during Virus Infection |
| Q34594080 | The HERV-K human endogenous retrovirus envelope protein antagonizes Tetherin antiviral activity |
| Q28742774 | The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism |
| Q35973592 | The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion |
| Q56988192 | The Interplay of Viral and Host Factors in Chikungunya Virus Infection: Targets for Antiviral Strategies |
| Q28606741 | The KT Jeang Retrovirology prize 2015: Paul Bieniasz |
| Q41504905 | The Molecular Switch of Telomere Phages: High Binding Specificity of the PY54 Cro Lytic Repressor to a Single Operator Site |
| Q89804627 | The N-glycosylation of Equine Tetherin Affects Antiviral Activity by Regulating Its Subcellular Localization |
| Q33564429 | The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin |
| Q37448307 | The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies |
| Q36301264 | The VCP/p97 and YOD1 Proteins Have Different Substrate-dependent Activities in Endoplasmic Reticulum-associated Degradation (ERAD) |
| Q34594813 | The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse adaptation |
| Q36824020 | The Vpu-interacting Protein SGTA Regulates Expression of a Non-glycosylated Tetherin Species |
| Q38269459 | The assembly of Vif ubiquitin E3 ligase for APOBEC3 degradation |
| Q57050797 | The avian influenza virus PA segment mediates strain-specific antagonism of BST-2/tetherin |
| Q38321444 | The cytoplasmic tail of retroviral envelope glycoproteins. |
| Q41762850 | The cytosolic N-terminus of CD317/tetherin is a membrane microdomain exclusion motif. |
| Q40055431 | The effect of bovine BST2A1 on the release and cell-to-cell transmission of retroviruses |
| Q45323651 | The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells. |
| Q21090506 | The great escape: viral strategies to counter BST-2/tetherin |
| Q34492477 | The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? |
| Q24605108 | The restriction factors of human immunodeficiency virus |
| Q26752737 | The role of BST-2/Tetherin in host protection and disease manifestation |
| Q34664616 | The role of BST2/tetherin in feline retrovirus infection |
| Q39010678 | The roles of ebolavirus glycoproteins in viral pathogenesis. |
| Q34992656 | The sheep tetherin paralog oBST2B blocks envelope glycoprotein incorporation into nascent retroviral virions |
| Q36492793 | The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release |
| Q35826562 | The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release |
| Q38210024 | The ubiquitin-conjugating system: multiple roles in viral replication and infection |
| Q35172704 | The viral restriction factor tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy |
| Q39717911 | Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication |
| Q27321247 | Three-Dimensional Structural Characterization of HIV-1 Tethered to Human Cells |
| Q47548056 | Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control |
| Q38181142 | Type I Interferon at the Interface of Antiviral Immunity and Immune Regulation: The Curious Case of HIV-1. |
| Q38348388 | Type I interferon: understanding its role in HIV pathogenesis and therapy |
| Q92681960 | Ubiquitination and SUMOylation in HIV Infection: Friends and Foes |
| Q31034125 | Ultra structural characterisation of tetherin - a protein capable of preventing viral release from the plasma membrane |
| Q92859937 | Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses |
| Q35075884 | Upregulation of innate antiviral restricting factor expression in the cord blood and decidual tissue of HIV-infected mothers. |
| Q43047324 | Viperin targets flavivirus virulence by inducing assembly of non-infectious capsid particles |
| Q27000898 | Viral Membrane Channels: Role and Function in the Virus Life Cycle |
| Q35778560 | Viral Restriction Activity of Feline BST2 Is Independent of Its N-Glycosylation and Induction of NF-κB Activation |
| Q35151120 | Viral miniproteins |
| Q37755567 | Viral proteins function as ion channels. |
| Q90470251 | Virion-incorporated PSGL-1 and CD43 inhibit both cell-free infection and transinfection of HIV-1 by preventing virus-cell binding |
| Q38023155 | Viroporins: structure and biological functions. |
| Q37726587 | Virus cell-to-cell transmission. |
| Q35826825 | Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling |
| Q26801489 | Vpu Protein: The Viroporin Encoded by HIV-1 |
| Q34697856 | Vpu binds directly to tetherin and displaces it from nascent virions |
| Q34532245 | Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail |
| Q84561051 | Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation |
| Q35089155 | Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon |
| Q24336663 | Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation |
| Q34312227 | Zinc-finger antiviral protein inhibits XMRV infection |
| Q109649533 | Zn‐Induced Interactions Between SARS‐CoV‐2 orf7a and BST2/Tetherin |
| Q39594626 | β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release |
| Q57811810 | βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin |
Search more.